Capricor Therapeutics Inc Stock Nasdaq
Stocks
US14070B1017
Biotechnology & Medical Research
| Market Cap | 1.15B 1B 931M 857M 1.62B 110B 1.63B 11.11B 4.35B 54.09B 4.3B 4.21B 187B | P/E 2026 * |
-33.4x | P/E 2027 * | -30.2x |
|---|---|---|---|---|---|
| Enterprise Value | 1.15B 1B 931M 857M 1.62B 110B 1.63B 11.11B 4.35B 54.09B 4.3B 4.21B 187B | EV / Sales 2026 * |
9.71x | EV / Sales 2027 * | 9.37x |
| Free-Float |
90.53% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Capricor Therapeutics Inc
| 1 day | +10.01% |
| Manager | Title | Age | Since |
|---|---|---|---|
Linda Marbán
CEO | Chief Executive Officer | 62 | 2013-11-19 |
Anthony Bergmann
DFI | Director of Finance/CFO | 40 | 2017-12-31 |
Michael Binks
CTO | Chief Tech/Sci/R&D Officer | - | 2025-05-12 |
| Director | Title | Age | Since |
|---|---|---|---|
Frank Litvack
CHM | Chairman | 70 | 2013-10-31 |
David Musket
BRD | Director/Board Member | 68 | 2013-11-19 |
George Dunbar
BRD | Director/Board Member | 79 | 2013-11-19 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +10.01% | -11.80% | - | - | 1.13B | |
| +0.88% | +0.08% | +54.51% | +58.77% | 53.79B | |
| +1.80% | +5.16% | +53.09% | +86.95% | 54.69B | |
| +1.50% | -0.48% | +5.91% | +410.19% | 23.2B | |
| +0.18% | +2.51% | -16.08% | -14.29% | 23.31B | |
| +1.46% | +4.02% | +35.97% | -4.03% | 20.03B | |
| +0.30% | -2.68% | +30.50% | -33.10% | 17.31B | |
| 0.00% | -6.00% | +163.95% | +284.69% | 14.99B | |
| +1.49% | +1.49% | +31.63% | +654.98% | 15.36B | |
| +1.06% | +0.14% | +26.20% | +182.44% | 13.96B | |
| Average | +1.87% | -1.84% | +42.85% | +180.73% | 26.29B | |
| Weighted average by Cap. | +1.13% | -1.78% | +42.92% | +140.83% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 118M 103M 95.9M 88.26M 166M 11.37B 168M 1.14B 448M 5.57B 443M 434M 19.24B | 122M 107M 99.35M 91.45M 172M 11.78B 175M 1.19B 464M 5.77B 459M 449M 19.94B |
| Net income | -28.4M -24.9M -23.07M -21.23M -40.04M -2.74B -40.52M -275M -108M -1.34B -107M -104M -4.63B | -48.17M -42.22M -39.12M -36.01M -67.89M -4.64B -68.72M -467M -183M -2.27B -181M -177M -7.85B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
